Search research articles
Contact Us
Filters
Showing results (101-110 of 143) with videos related to
Page
of 15
Sort By:
Circulation
|
April 9, 2021
Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF
Pardeep S Jhund, Piotr Ponikowski, Kieran F Docherty, et al.
Circulation
|
November 19, 2019
Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial
Mikhail N Kosiborod, Pardeep S Jhund, Kieran F Docherty, et al.
European Journal of Heart Failure
|
May 3, 2024
Dapagliflozin and quality of life measured using the EuroQol 5-dimension questionnaire in patients with heart failure with reduced and mildly reduced/preserved ejection fraction
Mingming Yang, Toru Kondo, Atefeh Talebi, et al.
Circulation. Heart Failure
|
October 27, 2023
Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER
Toru Kondo, Jawad H Butt, James P Curtain, et al.
Circulation
|
August 16, 2022
Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF
Kieran F Docherty, Paul Welsh, Subodh Verma, et al.
Circulation
|
April 20, 2022
Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF
Carly Adamson, Kieran F Docherty, Hiddo J L Heerspink, et al.
JAMA Cardiology
|
February 22, 2023
Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid-Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout: A Patient-Level Pooled Meta-analysis of DAPA-HF and DELIVER
Jawad H Butt, Kieran F Docherty, Brian L Claggett, et al.
Diabetes Care
|
December 23, 2020
Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF
Silvio E Inzucchi, Kieran F Docherty, Lars Køber, et al.
European Journal of Heart Failure
|
May 16, 2025
Anaemia in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial
Misato Chimura, Mingming Yang, Alasdair D Henderson, et al.
JACC. Heart Failure
|
March 15, 2025
Interleukin-6 in Heart Failure With Reduced Ejection Fraction and the Effect of Dapagliflozin: An Exploratory Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial
Kieran F Docherty, Kirsty McDowell, Paul Welsh, et al.
Page
of 15
Search research articles
Search
Showing results (101-110 of 143) with videos related to
Sort By:
Page
of 15
Circulation
|
April 9, 2021
Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF
Pardeep S Jhund, Piotr Ponikowski, Kieran F Docherty, et al.
Circulation
|
November 19, 2019
Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial
Mikhail N Kosiborod, Pardeep S Jhund, Kieran F Docherty, et al.
European Journal of Heart Failure
|
May 3, 2024
Dapagliflozin and quality of life measured using the EuroQol 5-dimension questionnaire in patients with heart failure with reduced and mildly reduced/preserved ejection fraction
Mingming Yang, Toru Kondo, Atefeh Talebi, et al.
Circulation. Heart Failure
|
October 27, 2023
Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER
Toru Kondo, Jawad H Butt, James P Curtain, et al.
Circulation
|
August 16, 2022
Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF
Kieran F Docherty, Paul Welsh, Subodh Verma, et al.
Circulation
|
April 20, 2022
Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF
Carly Adamson, Kieran F Docherty, Hiddo J L Heerspink, et al.
JAMA Cardiology
|
February 22, 2023
Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid-Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout: A Patient-Level Pooled Meta-analysis of DAPA-HF and DELIVER
Jawad H Butt, Kieran F Docherty, Brian L Claggett, et al.
Diabetes Care
|
December 23, 2020
Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF
Silvio E Inzucchi, Kieran F Docherty, Lars Køber, et al.
European Journal of Heart Failure
|
May 16, 2025
Anaemia in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial
Misato Chimura, Mingming Yang, Alasdair D Henderson, et al.
JACC. Heart Failure
|
March 15, 2025
Interleukin-6 in Heart Failure With Reduced Ejection Fraction and the Effect of Dapagliflozin: An Exploratory Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial
Kieran F Docherty, Kirsty McDowell, Paul Welsh, et al.
Page
of 15